Generic Name and Formulations:
Lepirudin 50mg/vial; pwd for IV inj or infusion after reconstitution and dilution; contains mannitol.
Indications for REFLUDAN:
Heparin-induced thrombocytopenia (HIT) and associated thromboembolic disease.
Do not start treatment if baseline aPTT ratio ≥2.5 to avoid initial overdosing. ≤110kg: Initially 0.4mg/kg by slow IV bolus inj over 15–20 seconds, follow by 0.15mg/kg/hour as a continuous IV infusion for 2–10 days or longer if clinically needed. >110kg: max initial bolus dose 44mg; max initial infusion dose 16.5mg/hour. Adjust dose based on aPTT ratio; usual target range (1.5–2.5). Monitor 1st aPTT determination at 4 hours after start of infusion and at least once daily during therapy; more frequently with renal impairment or serious liver injury. Dose adjustments, renal impairment, concomitant thrombolytic therapy: see literature.
Recent puncture or anomaly of vessels or organs. Recent cerebrovascular accident, stroke, intracerebral surgery, or other neuraxail procedures. Severe uncontrolled hypertension. Bacterial endocarditis. Hemorrhagic diathesis. Recent major surgery or major bleeding (eg, intracranial, GI, intraocular, or pulmonary). Active peptic ulcer. Advanced renal impairment. Monitor aPTT ratio and creatinine clearance prior to and during therapy. Hepatic impairment. Pregnancy (Cat.B). Nursing mothers: not recommended.
Direct thrombin inhibitor (recombinant hirudin).
Concomitant thrombolytics (eg, rt-PA, streptokinase), drugs that affect platelets, coumarin derivatives: increase risk of bleeding and potentiate effect of lepirudin on aPTT prolongation.
Bleeding, abnormal liver function, anaphylactic reactions (esp with re-exposure; may be fatal), multiorgan failure, antibody formation.
Sign Up for Free e-newsletters
- Choice of Breast Reconstruction After Mastectomy Affects Satisfaction, Quality of Life
- Bariatric Surgery Reduced Risk of Some Cancers in Obese Patients
- Carfilzomib Benefits May Outweigh Cardiovascular Risk in Multiple Myeloma
- The Caregivers' Cancer Journey
- Genetic Link Between Depression and Breast Cancer Remains Unclear
- Implementing an Ambulatory Adherence Program May Improve Oral Anticancer Medications Compliance
- Exercise Habits Influence Mortality in Adult Survivors of Childhood Cancer
- Managing Dyspnea With Fentanyl in Patients With Cancer at End of Life
- CALM: A Depression Intervention for Cancer Patients at the End of Life
- High BMI Among Premenopausal Women May Improve Risk for Breast Cancer
- Fertility Preservation in Hodgkin's Lymphoma Patients That Undergo Targeted Molecular Therapies: An Important Step Forward From the Chemotherapy Era
- Survey of ACEP Councilors Reveals NP, PA Staffing Models, Practice Patterns Vary
- Breath Analysis May Be an Effective Diagnostic for Pancreatic Cancer
- Genetic Susceptibility to Pancreatic Cancer Linked to 6 Specific Gene Mutations
- Dinner Hour and Sleep Habits Affect Risk of Breast, Prostate Cancers
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|